DK1253935T3 - Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde - Google Patents

Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde

Info

Publication number
DK1253935T3
DK1253935T3 DK01902406T DK01902406T DK1253935T3 DK 1253935 T3 DK1253935 T3 DK 1253935T3 DK 01902406 T DK01902406 T DK 01902406T DK 01902406 T DK01902406 T DK 01902406T DK 1253935 T3 DK1253935 T3 DK 1253935T3
Authority
DK
Denmark
Prior art keywords
growth factor
stroke
prevent
ischemic disease
placental growth
Prior art date
Application number
DK01902406T
Other languages
English (en)
Inventor
Desire Collen
Peter Carmeliet
Original Assignee
D Collen Res Foundation Vzw
Flanders Interuniversity Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by D Collen Res Foundation Vzw, Flanders Interuniversity Inst filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of DK1253935T3 publication Critical patent/DK1253935T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Clamps And Clips (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01902406T 2000-02-04 2001-02-05 Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde DK1253935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
US23659400P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
DK1253935T3 true DK1253935T3 (da) 2006-09-04

Family

ID=26243563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902406T DK1253935T3 (da) 2000-02-04 2001-02-05 Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde

Country Status (9)

Country Link
EP (1) EP1253935B1 (da)
JP (1) JP4969753B2 (da)
AT (1) ATE324905T1 (da)
AU (2) AU4643501A (da)
DE (1) DE60119285T2 (da)
DK (1) DK1253935T3 (da)
ES (1) ES2263582T3 (da)
PT (1) PT1253935E (da)
WO (2) WO2001057181A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
JP4741249B2 (ja) 2002-11-16 2011-08-03 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
EP2295449A1 (en) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimeric form
EP3586867A3 (en) * 2013-01-28 2020-04-08 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
NZ514872A (en) * 1997-04-25 2005-01-28 Collateral Therapeutics Truncated VEGF-B, VRF-2, VEGF-C, PlGF, VEGF-3, poxvirus ORF-1 and poxvirus ORF-2 proteins
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
CN1295617A (zh) * 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体

Also Published As

Publication number Publication date
AU2001230243A1 (en) 2001-08-14
AU4643501A (en) 2001-08-14
WO2001057181A2 (en) 2001-08-09
ATE324905T1 (de) 2006-06-15
PT1253935E (pt) 2006-08-31
WO2001056593A3 (en) 2002-04-25
DE60119285D1 (de) 2006-06-08
EP1253935A2 (en) 2002-11-06
ES2263582T3 (es) 2006-12-16
EP1253935B1 (en) 2006-05-03
WO2001056593A2 (en) 2001-08-09
DE60119285T2 (de) 2007-05-10
JP2003521522A (ja) 2003-07-15
JP4969753B2 (ja) 2012-07-04

Similar Documents

Publication Publication Date Title
BR0114390A (pt) éteres de 7-desmetilrapamicina
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1419154T3 (da) Rapamycin-29-enoler
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
PT1187918E (pt) Antagonistas de tek
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
DK1334194T3 (da) Afbildning, diagnosticering og behandling af sygdom
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
AR028411A1 (es) Secuencias de nuclentidos relacionadas con el aumento o la disminucion del endice de ovulacion en mameferos
TR200200278T2 (tr) Kalsilitik bileşimler
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60003074D1 (de) Fusidinsäure-derivate
ECSP045161A (es) Piperidin-2,6-diona sustituida con heterociclo en la posición 3
DK1194158T3 (da) Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning
DK1311486T3 (da) Anvendelser af thaliporphin eller dets derivater til behandling af hjertesygdomme og fremstilling af samme